pep4c

Discontinued Product

pep4c (Cat. No. 1596) has been withdrawn from sale for commercial reasons.
Description: Inactive control peptide for pep2m (Cat. No. 1595)
Alternative Names: GluR4cr
Datasheet
Citations
Reviews
Literature (4)

Biological Activity for pep4c

pep4c is an inactive control peptide analog of pep2m, a peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF).

Active Analog also available.

Technical Data for pep4c

M. Wt 1146.42
Formula C48H91N17O13S
Sequence KRMKVAKSAQ
Storage Desiccate at -20°C
CAS Number 243843-43-8
PubChem ID 90471151
InChI Key PUDVEKDEUNWDBZ-SKYKFSGJSA-N
Smiles [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for pep4c

Certificate of Analysis / Product Datasheet
Select another batch:

References for pep4c

References are publications that support the biological activity of the product.

Collingridge and Isaac (2003) Functional roles of protein interactions with AMPA and kainate receptors. Neurosci.Res. 47 3 PMID: 12941441

Luscher et al (1999) Role of AMPA receptor cycling in synaptic transmission and plasticity. Neuron 24 649 PMID: 10595516

Luthi et al (1999) Hippocampal LTD expression involves a pool of AMPARs regulated by the NSF-GluR2 interaction. Neuron 24 389 PMID: 10571232

Nishimune et al (1998) NSF binding to GluR2 regulates synaptic transmission. Neuron 21 87 PMID: 9697854

Noel et al (1999) Surface expression of AMPA receptors in hippocampal neurons is regulated by an NSF-dependent mechanism. Neuron 23 365 PMID: 10399941

View Related Products by Target

Keywords: pep4c, pep4c supplier, Inactive, control, peptide, 1595, Glutamate, AMPA, Receptors, iGlu, Ionotropic, GluR4cr, 1596, Tocris Bioscience

Citations for pep4c

Citations are publications that use Tocris products.

Currently there are no citations for pep4c.

Reviews for pep4c

There are currently no reviews for this product. Be the first to review pep4c and earn rewards!

Have you used pep4c?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.